Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2
Latest Information Update: 04 Mar 2024
At a glance
- Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
 - Indications COVID 2019 infections
 - Focus Pharmacodynamics
 
Most Recent Events
- 28 Feb 2024 Status changed from active, no longer recruiting to completed.
 - 28 Nov 2023 Planned End Date changed from 27 Jun 2023 to 31 Dec 2023.
 - 10 Feb 2023 Planned End Date changed from 7 Jun 2023 to 27 Jun 2023.